Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fibrostop: Peginterferon for Liver Fibrosis in HIV/HCV Co-infected Patients
NCT00122616Phase 3Completed
- Sponsor
- ANRS
- Start
- Nov 2003
- Primary completion
- Mar 2009
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of peginterferon alfa-2a in hepatitis C (HCV) and Liver Fibrosis (LF) (2 arms), sponsored by ANRS. Primary endpoint: Percentage of patients who experienced one point decreases of their fibrosis histological score (Metavir) at 96 weeks. Started Nov 2003; status: completed.
02
Drugs
peginterferon alfa-2a
03
Conditions
hepatitis C (HCV)Liver Fibrosis (LF)
Beyond the preview
Go deeper on NCT00122616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00122616.